PharmAla Biotech
Canada’s sole GMP‑grade MDMA supplier, advancing safe MDXX drug candidates for mental‑health therapeutics.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Canada’s sole GMP‑grade MDMA supplier, advancing safe MDXX drug candidates for mental‑health therapeutics.
PsychiatryNeurodevelopmental Disorders
Technology Platform
GMP manufacturing of clinical‑grade MDMA and AI‑driven phenethylamine discovery (Phenesafe.AI) for novel MDXX analogues.
Opportunities
Growing demand for GMP‑grade MDMA and a differentiated AI‑driven pipeline of safer MDXX analogues position PharmAla to capture a niche supply and licensing market in psychedelic therapeutics.
Risk Factors
Regulatory restrictions on controlled substances, reliance on third‑party manufacturing partners, and the need for substantial capital to advance MDXX candidates into clinical trials.
Competitive Landscape
Key competitors include MAPS, Compass Pathways, and MindMed, which focus on therapeutic development; PharmAla differentiates by providing the only North‑American GMP MDMA supply and a safety‑focused, AI‑enhanced MDXX discovery platform.